Recent Updates
Recently added Catalysts
TLX Positive Sentiment

Investor Education Webinar: The Future of Prostate Imaging: What do physicians want?

Monday, March 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Telix is hosting an investor education webinar on March 4, 2026, focusing on innovations in PSMA-PET/CT imaging for prostate cancer. The event will feature key opinion leaders discussing physician perspectives. Moderated by Dr. David N. Cade, the webinar aims to provide valuable insights for investors.
Price reaction · baseline $7.25 (2026-02-27 close) · hit pre-market · 1 other TLX headline(s) in the window, move may be shared
day 0 close
-2.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Focus on innovations in prostate cancer imaging.
  • Engagement with key opinion leaders in the field.
  • Opportunity for investors to gain insights.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

Investor Education Webinar The Future of Prostate Imaging: What do physicians want?

Melbourne (Australia) and Indianapolis (United States) | 2 March 2026
Telix invites investors to join a webinar with key opinion leaders to discuss a physician’s perspective on innovations in PSMA-PET/CT imaging for prostate cancer.
Speakers:
The webinar will be moderated by David N. Cade, MD, Telix Group Chief Medical Officer.
The webinar will be held on:
EST: Wednesday March 4, 2026, 5:30 p.m.
AEDT: Thursday March 5, 2026, 9:30 a.m.
The event will run for approximately one hour.
Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/n87mam6r

Frequently Asked Questions

What is the focus of the Telix webinar?

The webinar focuses on innovations in PSMA-PET/CT imaging for prostate cancer.

When will the webinar take place?

The webinar is scheduled for March 4, 2026, at 5:30 p.m. EST.

Who will moderate the webinar?

The webinar will be moderated by Dr. David N. Cade, Telix's Chief Medical Officer.

How long will the webinar last?

The event is expected to run for approximately one hour.

How can participants register for the webinar?

Participants can register for the webcast via the provided link.

ShareAdd on Google
Tags: TLX Viatris Investor Conferences Healthcare Telix prostate cancer PSMA-PET/CT investor webinar medical imaging
Last updated: Mar 2, 2026

Biotech snapshot

Lead asset
131I-IPAPhase 1
Neoplastic Disease →

Catalyst track record

+13%
best trade around TLX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for TLX.

See every catalyst's timing & PoA →